Abstract：Objective: To evaluate the efficacy of metoprolol and ezetimibe in the treatment of coronary heart disease in the elderly and their influence on renin-angiotensin-aldosterone system (RAAS). Methods: A total of 187 elderly patients with coronary heart disease who were admitted to our hospital from June 2019 to June 2021 were included in the combination group (n=93) and control group (n=94) by stratified random method. Both groups were treated with conventional medication for coronary heart disease and metoprolol, while the combination group was additionally treated with ezetimibe for three months. The changes of cardiac function, myocardial remodeling index and blood lipid level in the two groups were compared before and after treatment. The RAAS function was evaluated according to the changes of renin activity (PRA), angiotensin II (Ang II) and aldosterone (ALD) levels in patients. Results: After treatment, the cardiac output (CO), left ventricular ejection fraction (LVEF) and peak early diastolic velocity/peak late diastolic velocity (E/A) of the two groups were all higher than those before treatment, and the increase of the combined group was more significant than that of the control group, with statistical significance (P<0.05). After treatment, the left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) of the two groups decreased compared with those before treatment, and the decrease of the combined group was more significant than that of the control group, with statistical significance (P<0.05). After treatment, the triglyceride (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) of the two groups decreased compared with those before treatment, and the decrease of the combined group was more significant than that of the control group, with statistical significance (P<0.05). After treatment, the PRA, AngⅡ ⅱ and ALD of the two groups were lower than those before treatment, and the decrease of the combined group was more significant than that of the control group, with statistical significance (P<0.05). There were no obvious adverse reactions in both groups during treatment. After treatment, the total effective rate of the combined group was 93.55%, which was higher than 82.98% of the control group (P<0.05). Conclusion: The combination of metoprolol and ezetimibe can further regulate blood lipid levels in elderly patients with coronary heart disease, achieve the purpose of improving cardiac function, inhibiting myocardial remodeling and regulating RAAS function, and help to improve the prognosis of patients.
蔡吉, 肖楠川, 张一洁, 李莹. 美托洛尔依折麦布联合治疗老年冠心病的疗效及对RAAS的影响[J]. 河北医学, 2023, 29(1): 167-172.
CAI Ji, XIAO Nanchuan, ZHANG Yijie, et al. Effect of Metoprolol and Ezetimibe Combined in the Treatment of Coronary Heart Disease in the Elderly and Its Influence on RAAS. HeBei Med, 2023, 29(1): 167-172.
[1] 李丽亚,许丁.依折麦布与阿托伐他汀联用治疗血脂控制不佳老年冠心病的临床观察[J].中国社区医师,2020,36(2):69-70. [2] Braun M M,Stevens W A,Barstow C.Stable coronary artery disease:treatment[J].American family physician,2018,97(6):376-384. [3] Gorniak A,Czapor-Irzabek H,Zocinska A,et al.Physicochemical and dissolution properties of ezetimibe-aspirin binary system in development of fixed-dose combinations[J].Journal of Thermal Analysis and Calorimetry,2021,144(4):1219-1227. [4] Habib M.Cardio-cerebral Infarction syndrome (CCIS):definition,diagnosis,pathophysiology and treatment[J].Cardiovascular Research,2021,5(2):84-93. [5] Nguyen T,Wang Z A.Cardiovascular screening and early detection of heart disease in adults with chronic kidney disease[J].The Journal for Nurse Practitioners,2019,15(1):34-40. [6] Tulyaganova D K,Alyavi A L,Sabirjanova Z T,et al.Modern view of the inflammatory cytokines in coronary artery disease[J].Glob Acad Med Sci,2019,1(1):9-12. [7] Wang N,Fulcher J,Abeysuriya N,et al.Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events:a systematic review and meta-analysis of randomised trials including 327 037 participants[J].The lancet Diabetes & endocrinology,2020,8(1):36-49. [8] Li Y H,Wang Y C,Wang Y C,et al.2018 guidelines of the taiwan society of cardiology,taiwan society of emergency medicine and taiwan society of cardiovascular interventions for the management of non ST-segment elevation acute coronary syndrome[J].Journal of the Formosan Medical Association,2018,117(9):766-790. [9] Luo Y,Zheng M,Zhang Y,et al.Familial hypercholesterolemia with early coronary atherosclerotic heart disease:a case report[J].Experimental and Therapeutic Medicine,2019,18(2):981-986. [10] Jensen R V,Hjortbak M V,Btker H E.Ischemic heart disease:an update seminars in nuclear medicine[J].WB Saunders,2020,50(3):195-207.
2023, Vol. 29 
冀公网安备13080202000677号